Daratumumab combinations: What can we learn?

Blood

Volumn 130, Issue 8, 2017, Pages 957-958

  Kastritis, Efstathios ^a   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DARATUMUMAB; DEXAMETHASONE; POMALIDOMIDE; MONOCLONAL ANTIBODY;

DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOTHERAPY; MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; MULTIPLE MYELOMA;

ANTIBODIES, MONOCLONAL; MULTIPLE MYELOMA;

EID: 85028465447     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-07-793349     Document Type: Review

References (10)

1. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974-981.
2. Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016; 30(2):399-408.
3. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
4. Chiu C, Casneuf T, Axel A, et al. Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: Results from a phase 3 randomized study (POLLUX) [abstract]. Blood. 2016;128(22). Abstract 4531.
5. Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959-970.
6. Boxhammer R, Steidl S, Endell J. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide [abstract]. ASCO. 2015;33(15). Abstract 8588.
7. Chen L, Beyers LA, Ullrich S, Wistuba II, Qin X-F, Gibbons DL. CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis [abstract]. J Clin Oncol. 2017;35(suppl 7S). Abstract 79.
8. Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): A phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497-503.
9. Usmani SZ, Dimopoulos MA, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: Updated analysis of Pollux [abstract]. Blood. 2016;128(22). Abstract 1151.
10. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.